Mechanisms of resistance to T cell‐based immunotherapy in head and neck cancer
- 10 April 2020
- journal article
- review article
- Published by Wiley in Head & Neck
- Vol. 42 (9), 2722-2733
- https://doi.org/10.1002/hed.26158
Abstract
Background Most current approved or investigational immunotherapeutic approaches for head and neck squamous cell carcinoma are aimed at activating T cells. The majority of patients receiving such immunotherapy do not demonstrate durable tumor remission. Methods Original articles covering tumor heterogeneity, immunoediting, immune escape, and local tumor immunosuppression were reviewed. Results In the face of immune pressure, subclones susceptible to T cell killing are eliminated, leaving behind resistant tumor clones in a process known as immunoediting. Such subclones of tumor cells that are resistant to T cell killing may remain sensitive to natural killer (NK) cell detection and elimination, suggesting that patients harboring such tumors may benefit from combination of T and NK cell‐based immunotherapy. Even in the setting of optimal immunotherapy, the immunosuppressive tumor microenvironment may arrogate effector immune responses through a number of distinct mechanisms. Conclusions Highly effective immunotherapy will likely require multimodality approaches targeting independent mechanisms of immune activation.Keywords
Funding Information
- Colgate-Palmolive Company
- American Association for Dental Research
- Doris Duke Charitable Foundation
- Foundation for the National Institutes of Health
- National Institute on Deafness and Other Communication Disorders (DC000087)
This publication has 126 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patientsJCI Insight, 2013
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Expression of tumour-specific antigens underlies cancer immunoeditingNature, 2012
- The Two Faces of Interferon-γ in CancerClinical Cancer Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytesCancer Immunology, Immunotherapy, 2011
- Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) MonocytesCancer Research, 2010
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell functionThe Journal of Experimental Medicine, 2006